Scarica l'app Stockscreener
25.89
0.76%
0.1886
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.70
Aprire:
$25.77
Volume 24 ore:
18.30M
Relative Volume:
0.28
Capitalizzazione di mercato:
$147.17B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
15.09
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+0.60%
1M Prestazione:
+5.22%
6M Prestazione:
+12.00%
1 anno Prestazione:
+0.76%
Intervallo 1D:
$25.64
$25.96
Intervallo di 1 settimana:
$25.04
$25.96
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.89 | 146.12B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,010.09 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.07 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.68 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.97 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.58 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Sandoz, Pfizer Denied Bid to End Generic Drug Price-Fixing Case - Bloomberg Law News
2 Headwinds Facing Pfizer Stock Going Into 2026 - Yahoo Finance
Pfizer: The Market Is Still Wrong About It (NYSE:PFE) - Seeking Alpha
3 Reasons PFE is Risky and 1 Stock to Buy Instead - Finviz
How Does Pfizer Stock Stack Up Against Its Peers? - Trefis
Pfizer Inc. (PFE): A Bull Case Theory - Insider Monkey
Pharmaceutical Marketing Industry Trends and Emerging Opportunities 2025-2032 Featuring Syneos Health, McCann Health, Amgen, AXPIRA, Pfizer and MoreResearchAndMarkets.com - The AI Journal
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
What Trends Are Defining the Hemophilia Inhibitors Market Growth? - GlobeNewswire Inc.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025) - 24/7 Wall St.
Could This Fuel The Next Surge in Pfizer Stock - Trefis
Pharmacy Market size to cross $3.4 Trillion by 2035 | Pfizer Inc., - openPR.com
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
Jim Cramer on Pfizer: "I would hold on to it" - MSN
Jim Cramer on Pfizer: “I Would Hold on to It” - Insider Monkey
Jim Cramer on Pfizer: "I Would Hold on to It" - Finviz
Does PADCEV Keytruda Bladder Cancer Win Reshape The Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025) - ts2.tech
Pfizer : November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceBusinessCancerHealth Equity - MarketScreener
A Decade of Rewards: $68 Bil From Pfizer Stock - Trefis
Antiemetics Market Size, Forecast 2031 by Key Companies- - openPR.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Pfizer price leans on SMA supportForecast today03-12-2025 - Economies.com
Pfizer Inc (NYSE:PFE) S&P 500 Today Indicates Stable Clinical Demand - Kalkine Media
Pfizer Partner 3SBio To Raise $400 Million In Stock Sale - Forbes
MVP: Williams & Connolly's David M. Krinsky - Law360
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure - sharewise.com
Assessing Pfizer's (PFE) Valuation After Recent Share Price Rebound - Yahoo Finance
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance - BioSpace
Pfizer (PFE) Coverage Resumed by Citi with 'Neutral' Rating - GuruFocus
Pfizer’s Pivotal Moment: Can a December Strategy Reveal Spark a Turnaround? - AD HOC NEWS
Pfizer (PFE) Part of UK-US Drug Pricing Agreement - GuruFocus
3SBio Placement: Partnership with Pfizer Going Well; Digestible Deal - Smartkarma
Pfizer (PFE) Valuation in Focus After FDA Approves PADCEV Combo for Bladder Cancer - simplywall.st
Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts - ts2.tech
Pfizer Stock Price ForecastPFE Shares Surges Toward $30 With Metsera Deal & $7.2B Cost Cuts Drive 2026 Recovery - TradingNEWS
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield - ts2.tech
Pfizer: The Pharma Giant To Buy Right Now (NYSE:PFE) - Seeking Alpha
Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December - Seeking Alpha
With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns - Yahoo Finance
Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield - ts2.tech
Is Pfizer Stock Underperforming the Dow? - Barchart.com
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating - MSN
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet? - Nasdaq
Quarterly Risk: Will Pfizer Inc. stock beat EPS estimatesJuly 2025 Rallies & Low Risk Growth Stock Ideas - moha.gov.vn
How resilient is Pfizer Inc. stock in market downturnsJuly 2025 Sector Moves & Weekly Setup with ROI Potential - BỘ NỘI VỤ
U.S. Meibomian Gland Dysfunction Market to Get an Explosive - openPR.com
Does the Recent 3.3% Rally Change the Picture for Pfizer’s True Value? - simplywall.st
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook - ts2.tech
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):